(Q90963815)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30625281%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

title

Pharmacologic Targeting of Hypoxia-Inducible Factors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30625281%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

1

Gregg L Semenza

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30625281%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

publication date

1 January 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30625281%20AND%20SRC:MED&resulttype=core&format=json

Annual Review of Pharmacology and Toxicology

18 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30625281%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

volume

59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30625281%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

page(s)

379-403

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30625281%20AND%20SRC:MED&resulttype=core&format=json

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

18 April 2020

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/20459

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Laurenditerpenol, a new diterpene from the tropical marine alga Laurenciaintricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Grape seed extract inhibits VEGF expression via reducing HIF-1alpha protein expression

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-inducible factor 1 and cardiovascular disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Deletion of prolyl hydroxylase domain proteins (PHD1, PHD3) stabilizes hypoxia inducible factor-1 alpha, promotes neovascularization, and improves perfusion in a murine model of hind-limb ischemia.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Bisphenol A, an environmental endocrine-disrupting chemical, inhibits hypoxic response via degradation of hypoxia-inducible factor 1alpha (HIF-1alpha): structural requirement of bisphenol A for degradation of HIF-1alpha

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The last common ancestor of animals lacked the HIF pathway and respired in low-oxygen environments.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-inducible factors in physiology and medicine

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Chaperoning oncogenes: Hsp90 as a target of geldanamycin.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Plasticity of renal erythropoietin-producing cells governs fibrosis.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Erythropoietin messenger RNA levels in developing mice and transfer of 125I-erythropoietin by the placenta

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Discovery of Indenopyrazoles as a New Class of Hypoxia Inducible Factor (HIF)-1 Inhibitors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-Inducible Factors: Master Regulators of Cancer Progression

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Control of creatine metabolism by HIF is an endogenous mechanism of barrier regulation in colitis.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

NNC 55-0396, a T-type Ca2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1α signal transduction

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Reactivation of hepatic EPO synthesis in mice after PHD loss

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Targeting HIF1α eliminates cancer stem cells in hematological malignancies.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Targeting renal cell carcinoma with a HIF-2 antagonist.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Synthesis and biological evaluation of kresoxim-methyl analogues as novel inhibitors of hypoxia-inducible factor (HIF)-1 accumulation in cancer cells.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia Signaling Cascade for Erythropoietin Production in Hepatocytes.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Polycythemia in transgenic mice expressing the human erythropoietin gene

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Synergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Structural integration in hypoxia-inducible factors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Cardenolides from Calotropis gigantea as potent inhibitors of hypoxia-inducible factor-1 transcriptional activity.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Systems biology of oxygen homeostasis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

miR-210: fine-tuning the hypoxic response

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxic Adaptation in the Nervous System: Promise for Novel Therapeutics for Acute and Chronic Neurodegeneration

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Purification and characterization of hypoxia-inducible factor 1

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

A gain-of-function mutation in the HIF2A gene in familial erythrocytosis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

HIF-2alpha deletion promotes Kras-driven lung tumor development.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Acute postnatal ablation of Hif-2alpha results in anemia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

BMP9-regulated angiogenic signaling plays an important role in the osteogenic differentiation of mesenchymal progenitor cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Glycobiology and cancer: meeting summary and future diections

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Epidemiology of peripheral artery disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Oxygen sensing, homeostasis, and disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2alpha gain-of-function mutation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Increased Synthesis of Liver Erythropoietin with CKD.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Modulating the vascular response to limb ischemia: angiogenic and cell therapies.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Integrated molecular analysis of clear-cell renal cell carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Synthesis and evaluation of quinazolin-4-ones as hypoxia-inducible factor-1α inhibitors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Identification of a novel small molecule HIF-1alpha translation inhibitor

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Harnessing hypoxic adaptation to prevent, treat, and repair stroke.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Identification of Targets of the HIF-1 Inhibitor IDF-11774 Using Alkyne-Conjugated Photoaffinity Probes.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Short Hairpin RNA Silencing of PHD-2 Improves Neovascularization and Functional Outcomes in Diabetic Wounds and Ischemic Limbs

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The regulation of transcriptional repression in hypoxia.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Digoxin inhibits development of hypoxic pulmonary hypertension in mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

GL331 inhibits HIF-1alpha expression in a lung cancer model

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Prevalence of anemia in chronic kidney disease in the United States

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The energetics of genome complexity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Metabolic reprogramming by HIF-1 promotes the survival of bone marrow-derived angiogenic cells in ischemic tissue

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Vascular complications in Chuvash polycythemia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The EGLN-HIF O2-Sensing System: Multiple Inputs and Feedbacks

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Inflammatory bowel disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

HIF-Prolyl Hydroxylase 2 Inhibition Enhances the Efficiency of Mesenchymal Stem Cell-Based Therapies for the Treatment of Critical Limb Ischemia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Wogonin inhibits tumor angiogenesis via degradation of HIF-1α protein

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

HIF-dependent antitumorigenic effect of antioxidants in vivo

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Suppression of hypoxia-inducible factor 1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation rather than the mTORC1/4E-BP1 pathway

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV-PHARMTOX-010818-021637

Identifiers

DOI

10.1146/ANNUREV-PHARMTOX-010818-021637

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30625281%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

1 reference